In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayi.
Geldanamycin (GA) is a benzoquinone-containing ansamycin that inhibits heat shock protein 90. GA derivatives are being evaluated as anti-neoplastic agents, but their utility against parasites whose heat shock proteins (Hsps) have homology with human Hsp90 is unknown. The activities of four synthetic GA derivatives were tested in vitro using adult Brugia malayi and Schistosoma japonicum. Two of the derivatives, 17-N-allyl-17-demethoxygeldanamycin (17-AAG) and 17-N-(2-dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG), are currently in human clinical trials as anticancer drugs. Using concentrations considered safe peak plasma concentrations for these two derivatives, all four derivatives were active against both parasites. The less toxic derivative 17-AAG was as effective as GA in killing S. japonicum, and both DMAG and 5'-bromogeldanoxazinone were more active than 17-AAG against B. malayi. This work supports continued evaluation of ansamycin derivatives as broad spectrum antiparasitic agents.
The Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.
David
D
Wenkert
Bernadette
B
Ramirez
Yuehai
Y
Shen
Michael A
MA
Kron
Clin Cancer Res. 2007 Mar 15;13(6):1769-74
17363531
Acta Trop. 1981 Sep;38(3):277-88
6118036
Bioorg Med Chem. 2005 Aug 15;13(16):4960-71
15978816
BMC Evol Biol. 2009 Oct 22;9:254
19849843
Biochem Cell Biol. 2005 Dec;83(6):703-10
16333321
Acta Trop. 2009 Jul;111(1):82-5
19426668
Expert Opin Drug Discov. 2007 Oct;2(s1):S63-73
23489034
Invest New Drugs. 2006 Nov;24(6):543-6
16832603
Nat Rev Drug Discov. 2002 Sep;1(9):665-73
12209147
J Med Chem. 1995 Sep 15;38(19):3813-20
7562912
J Biol Chem. 1997 Sep 19;272(38):23843-50
9295332
Clin Cancer Res. 2007 Mar 15;13(6):1783-8
17363533
J Antibiot (Tokyo). 1970 Sep;23(9):442-7
5459626
Proc Soc Exp Biol Med. 2000 May;224(1):45-9
10782046
Nat Rev Drug Discov. 2008 Jan;7(1):84-99
18079757
Cell Stress Chaperones. 2003 Spring;8(1):93-104
12820659
Annu Rev Biochem. 2006;75:271-94
16756493
Clin Prostate Cancer. 2005 Sep;4(2):138-41
16197617
Malar J. 2003 Sep 15;2:30
14514358
Br J Pharmacol. 2005 Nov;146(6):769-80
16170327
Clin Cancer Res. 2007 Mar 15;13(6):1789-93
17363534
Expert Opin Drug Discov. 2007 Oct;2(s1):S75-82
23489035
Int J Parasitol. 2005 May;35(6):627-36
15862576
Curr Cancer Drug Targets. 2003 Oct;3(5):385-90
14529390
Expert Opin Drug Discov. 2007 Oct;2(s1):S53-61
23489033
Cancer Lett. 2004 Apr 8;206(2):149-57
15013520
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13
17090671
J Biol Chem. 2003 May 16;278(20):18336-45
12584193
PLoS Negl Trop Dis. 2010 Jun 15;4(6):e714
20559560
Curr Cancer Drug Targets. 2003 Oct;3(5):377-83
14529389
BMC Genomics. 2006 Jun 17;7:156
16780600
PLoS Comput Biol. 2007 Sep;3(9):1701-15
17941702
Cell. 1997 Apr 18;89(2):239-50
9108479